Wealthquest Corp Buys 22 Shares of Eli Lilly and Company (NYSE:LLY)

Wealthquest Corp grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,278 shares of the company’s stock after purchasing an additional 22 shares during the quarter. Eli Lilly and Company comprises approximately 0.3% of Wealthquest Corp’s investment portfolio, making the stock its 25th largest position. Wealthquest Corp’s holdings in Eli Lilly and Company were worth $4,075,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Beck Bode LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $15,036,000. XTX Topco Ltd bought a new position in Eli Lilly and Company during the second quarter worth $546,000. Mill Creek Capital Advisors LLC grew its holdings in Eli Lilly and Company by 8.4% in the second quarter. Mill Creek Capital Advisors LLC now owns 2,498 shares of the company’s stock worth $2,262,000 after purchasing an additional 194 shares during the period. Westwood Wealth Management increased its stake in Eli Lilly and Company by 20.1% in the second quarter. Westwood Wealth Management now owns 1,940 shares of the company’s stock valued at $1,756,000 after purchasing an additional 325 shares in the last quarter. Finally, Savoie Capital LLC acquired a new position in shares of Eli Lilly and Company during the second quarter valued at about $15,315,000. 82.53% of the stock is owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 2.2 %

Shares of NYSE LLY opened at $741.98 on Wednesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock has a market capitalization of $704.38 billion, a PE ratio of 80.21, a P/E/G ratio of 1.52 and a beta of 0.41. Eli Lilly and Company has a one year low of $614.82 and a one year high of $972.53. The business’s fifty day moving average price is $779.00 and its 200-day moving average price is $852.83.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period last year, the company earned $0.10 earnings per share. On average, equities research analysts anticipate that Eli Lilly and Company will post 12.98 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.81%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Eli Lilly and Company declared that its Board of Directors has approved a stock repurchase plan on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research analyst reports. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, January 1st. Wolfe Research assumed coverage on Eli Lilly and Company in a research report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price on the stock. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Finally, Bank of America reissued a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,002.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.